PetMed Express, Inc. (NASDAQ:PETS) – Analysts at Northcoast Research upped their Q3 2018 EPS estimates for PetMed Express in a report issued on Tuesday. Northcoast Research analyst E. Snyder now forecasts that the company will post earnings per share of $0.33 for the quarter, up from their prior estimate of $0.32. Northcoast Research also issued estimates for PetMed Express’ Q4 2018 earnings at $0.43 EPS, FY2018 earnings at $1.65 EPS, Q1 2019 earnings at $0.53 EPS, Q2 2019 earnings at $0.46 EPS, Q3 2019 earnings at $0.38 EPS, Q4 2019 earnings at $0.49 EPS and FY2019 earnings at $1.86 EPS.

PetMed Express (NASDAQ:PETS) last released its quarterly earnings results on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company had revenue of $66.70 million for the quarter, compared to analysts’ expectations of $63.41 million. During the same period last year, the company earned $0.24 EPS. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year.

PETS has been the subject of a number of other research reports. ValuEngine lowered shares of PetMed Express from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Credit Suisse Group reissued an “underperform” rating and set a $19.00 price target on shares of PetMed Express in a report on Monday, October 2nd. BidaskClub raised shares of PetMed Express from a “buy” rating to a “strong-buy” rating in a report on Saturday. Craig Hallum reissued a “hold” rating and set a $40.00 price target (down previously from $43.00) on shares of PetMed Express in a report on Monday, August 21st. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $42.00.

PetMed Express (PETS) traded up $0.82 during midday trading on Wednesday, reaching $43.51. 440,500 shares of the company traded hands, compared to its average volume of 648,455. The stock has a market capitalization of $879.60, a price-to-earnings ratio of 28.65, a price-to-earnings-growth ratio of 2.56 and a beta of 1.13. PetMed Express has a 52-week low of $19.21 and a 52-week high of $50.90.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in PetMed Express by 21.0% in the second quarter. Vanguard Group Inc. now owns 1,300,725 shares of the company’s stock worth $52,810,000 after purchasing an additional 225,474 shares during the period. Dimensional Fund Advisors LP raised its position in PetMed Express by 8.3% in the second quarter. Dimensional Fund Advisors LP now owns 860,601 shares of the company’s stock worth $34,940,000 after acquiring an additional 65,932 shares in the last quarter. Prudential Financial Inc. raised its position in PetMed Express by 552.8% in the third quarter. Prudential Financial Inc. now owns 824,434 shares of the company’s stock worth $27,330,000 after acquiring an additional 698,140 shares in the last quarter. Bank of New York Mellon Corp raised its position in PetMed Express by 13.1% in the second quarter. Bank of New York Mellon Corp now owns 432,057 shares of the company’s stock worth $17,542,000 after acquiring an additional 49,889 shares in the last quarter. Finally, Oaktop Capital Management II L.P. bought a new stake in PetMed Express in the second quarter worth about $15,171,000. 99.89% of the stock is owned by institutional investors and hedge funds.

In other news, Director Ronald J. Korn sold 1,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the completion of the transaction, the director now owns 73,833 shares of the company’s stock, valued at $2,626,239.81. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

The company also recently declared a quarterly dividend, which was paid on Friday, November 17th. Stockholders of record on Monday, November 6th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 1.84%. The ex-dividend date was Friday, November 3rd. PetMed Express’s dividend payout ratio (DPR) is 53.69%.

TRADEMARK VIOLATION NOTICE: “Northcoast Research Weighs in on PetMed Express, Inc.’s Q3 2018 Earnings (PETS)” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/13/northcoast-research-weighs-in-on-petmed-express-inc-s-q3-2018-earnings-pets.html.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Earnings History and Estimates for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.